title: Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study.
abstract: BACKGROUND
  Lanthanum carbonate (FOSRENOL®) is an effective, well-tolerated phosphate binder. The ability of lanthanum to reduce serum phosphorus levels to ≤5.5 mg/dL in patients with end-stage renal disease (ESRD) was assessed in a clinical practice setting.
  
  
  METHODS
  A 16-week, phase IV study enrolled 2763 patients at 223 US sites to evaluate the efficacy of lanthanum carbonate in controlling serum phosphorus in patients with ESRD, and patient and physician satisfaction with, and preference for, lanthanum carbonate after conversion from other phosphate-binder medications. Patients received lanthanum carbonate prescriptions from physicians. These prescriptions were filled at local pharmacies rather than obtaining medication at the clinical trial site. Changes from serum phosphorus baseline values were analyzed using paired t tests. Patient and physician preferences for lanthanum carbonate versus previous medications were assessed using binomial proportion tests. Satisfaction was analyzed using the McNemar test. Daily dose, tablet burden, and laboratory values including albumin-adjusted serum calcium, calcium × phosphorus product, and parathyroid hormone levels were secondary endpoints.
  
  
  RESULTS
  Serum phosphorus control (≤5.5 mg/dL) was effectively maintained in patients converting to lanthanum carbonate monotherapy; 41.6% of patients had controlled serum phosphate levels at 16 weeks. Patients and physicians expressed markedly higher satisfaction with lanthanum carbonate, and preferred lanthanum carbonate over previous medication. There were significant reductions in daily dose and daily tablet burden after conversion to lanthanum carbonate.
  
  
  CONCLUSIONS
  Serum phosphorus levels were effectively maintained in patients converted from other phosphate-binder medications to lanthanum carbonate, with increased satisfaction and reduced tablet burden.
  
  
  BACKGROUND
  ClinicalTrials.gov: NCT0016012.
authors.affiliation: Department of Medicine (Nephrology), Sierra View District Hospital, Porterville, CA, USA. vemurimd@gmail.com
authors.forename: Nirupama
authors.initials: N
authors.lastname: Vemuri
authors.forename: Michael F
authors.initials: MF
authors.lastname: Michelis
authors.forename: Albert
authors.initials: A
authors.lastname: Matalon
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001291:Attitude of Health Personnel; D005260:Female; D006801:Humans; D054559:Hyperphosphatemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications*; D007811:Lanthanum / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D010710:Phosphates / Q000378:metabolism; D010758:Phosphorus / Q000097:blood*; D010820:Physicians; D013607:Tablets / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D010710:Phosphates; D013607:Tablets; D010758:Phosphorus; C119467:lanthanum carbonate; D007811:Lanthanum